Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg

Muscle and Nerve

Volumn 40, Issue 3, 2009, Pages 374-380

  Carli, Luca ^a   Montecucco, Cesare ^a   Rossetto, Ornella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Botulinum toxin type A; Diffusion; N CAM; Neuromuscular junction

Indexed keywords

BOTULINUM TOXIN A; NERVE CELL ADHESION MOLECULE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DIFFUSION; DRUG FORMULATION; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LEG MUSCLE; MALE; MOUSE; MUSCLE CELL; MUSCLE DENERVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

ANIMALS; BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; GENE EXPRESSION REGULATION; HINDLIMB; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MUSCLE WEAKNESS; MUSCLE, SKELETAL; NEURAL CELL ADHESION MOLECULES; NEUROLOGIC EXAMINATION; NEUROMUSCULAR AGENTS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 69749107105     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21343     Document Type: Article

References (28)

1. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-1820.
2. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13(Suppl 4):10-19. (Pubitemid 44748279)
3. Arezzo JC, Litwak MS, Caputo FA, Meyer KE, Shopp GM. Spread of paralysis to nearby and distant noninjected muscles in a monkey hand model: comparison of bont-B and bont-A. In: Brin LC, Hallet M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p 123-133.
4. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
5. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392-399. (Pubitemid 20260525)
6. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum a toxin injections. Mov Disord 1994;9:31-39. (Pubitemid 24022612)
7. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-494. (Pubitemid 23226068)
8. Covault J, Sanes JR. Neural cell adhesion molecule (N-CAM) accumulates in denervated and paralyzed skeletal muscles. Proc Natl Acad Sci U S A 1985;82:4544-4548. (Pubitemid 15233157)
9. De Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999;96:3200-3205. (Pubitemid 29148868)
10. Dodd S, Rowell B, Vrabas I, Arrowsmith R, Weatherill P. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol 1998;5:181-186. (Pubitemid 28142570)
11. Eisele KH, Taylor HV. Dissociation of the 900 kda neurotoxin complex from C. botulinum under physiological conditions. Toxicon 2008;51:10.
12. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158-1160. (Pubitemid 26134671)
13. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov Disord 2004;19(Suppl 8):S53-59. (Pubitemid 38967512)
14. Flynn TC, Clark RE2. Botulinum toxin type B (Myobloc) versus botulinum toxin type A (Botox) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003;29:519-522; discussion, 522.
15. Hsu TSJ, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140:1351-1354.
16. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 2007;67:669-683. (Pubitemid 46535642)
17. Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002;96:105-113. (Pubitemid 34087038)
18. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005;5:274-279. (Pubitemid 40674251)
19. Moore SE, Walsh FS. Nerve dependent regulation of neural cell adhesion molecule expression in skeletal muscle. Neuroscience 1986;18:499-505.
20. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 2004;19(Suppl 8):S137-141. (Pubitemid 38967523)
21. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13(Suppl 1):2-10.
22. Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001;39:27-41. (Pubitemid 30628927)
23. Rossetto O, Morbiato L, Caccin P, Rigoni M, Montecucco C. Presynaptic enzymatic neurotoxins. J Neurochem 2006;97:1534-1545.
24. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-766.
25. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991;101:960-964.
26. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-969. (Pubitemid 23246323)
27. Simpson DM, Gracies J, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698. (Pubitemid 351644137)
28. Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 2008;41:897-902.